Toyama And Eisai Re-File Iguratimod For Rheumatoid Arthritis
This article was originally published in PharmAsia News
Executive Summary
Toyoma Chemical and Eisai Inc. re-submitted a new drug application for iguratimod in Japan after they withdraw the previous application in 2009